Clinical Trial Search

Primary: Clinical Response Rate of an Induction Regimen Consisting of Irinotecan, Cisplatin and Cetuximab — 40 percentage of paticipants

Primary: Inventory of Depressive Symptomatology- Clinician Rated (IDS-C) Scale — 22.7; 9.5 percentage of improved participants

Primary: PSA Response Analyzed Using the PCWG2 Definition — 1; 16 participants

Primary: Number of Participants With First Cycle Dose-limiting Toxicities (DLTs) — 2; 1; 3 participants

Primary: Adverse Events — 100; 16.67 percentage of participants

Primary: Percent Change in the Average Daily Pain Score From Baseline to Between Weeks 2 and 8 — -27.44; -20.85 percentage change — p=0.025

Primary: Change From Baseline to End of Month 6 in Prothrombin Fragment 1+2 Levels — 169.53; 157.99; 592.29 pmol/L — p=0.958

Primary: ADHD Rating Scale IV — 18.0; 21.3 units on a scale

Primary: Adjudicated Incidence of Bleeding Events — 5.5; 12.7; 7.3; 18.3 percent of subjects with outcome event — p=.367

Primary: Percent Change in Range of Motion From Baseline to 180 Days — 67; 33 percentage of change

Primary: Strength Performance Outcomes — 119.48; 120.45; 132.47; 129.37 Kg — p=.38

Primary: Adverse Events — 2 participants

Primary: Change From Baseline in 17-item Hamilton Raing Scale for Depression (HAM-D17) Total Score at Week 8 or Early Termination — -9.25; -10.76; -10.37 Units on a scale — p=0.031

Primary: Change in Mean Weekly Glucose Concentrations — 1; -10; -10; -0.3 mg/dl

Primary: Change in Insomnia Severity Index From Baseline to Post-intervention — -4.93; -6.36; 1.04; -1.43 units on a scale